-
Je něco špatně v tomto záznamu ?
Large vestibular schwannomas: long-term outcomes after stereotactic radiosurgery
D. Stastna, D. Urgosik, T. Chytka, R. Liscak
Jazyk angličtina Země Švédsko
Typ dokumentu časopisecké články
- MeSH
- lidé MeSH
- následné studie MeSH
- radiochirurgie * MeSH
- retrospektivní studie MeSH
- tumor burden MeSH
- vestibulární schwannom * diagnostické zobrazování radioterapie chirurgie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: Stereotactic radiosurgery (SRS) is an established treatment option of small/medium-sized vestibular schwannomas (VSs). Concerning management of the large VSs, primary SRS remains a controversial option. Our retrospective study analyzes long-term radiological and clinical outcomes of SRS in large VSs. MATERIAL AND METHODS: We retrospectively analyzed 73 patients with single large VS, treated with SRS. Inclusion criteria were: tumor volume >4 cm3, follow-up >2 years, radiological (3D-volumetric studies) and clinical follow-up. SRS was either primary (94.5%) or secondary (5.5%) treatment. The median marginal dose (50%-isodose line) was 12Gy (11.5-12Gy). Fisher exact test, t-test, ANOVA, Kaplan-Meier and Cox regression models were performed when appropriate RESULTS: The median follow-up was 5.5 years. The median VS volume at SRS was 6.5 cm3 (range 4-14.2 cm3). The tumor control rates assessed from Kaplan-Meier curve were 88.3%, 82.4% and 74.7% 5.8 and 10 years after SRS, respectively. Tumor shrinkage was observed in 83.6% of patients (n=61), unchanged volume in 4.1% patients (n=3) and progression in 12.3% (n=9). The median tumor volume significantly decreased to 4.0 cm3, measured at 5-year follow-up (p<0.0001). Large cystic VSs responded better to SRS then homogeneous. Pre-SRS serviceable hearing was present in 37% of patients; 55% of these had hearing preserved after treatment. After SRS, new facial palsy (House-Brackmann gr. III-VI) appeared in 4.1% of patients; 9.6% of patients had transient brainstem/cranial nerves edema. For tumor progression, 8.2% of patients underwent resection, 2.8% of patients repeated SRS. CONCLUSION: Our results are showing that SRS might be safe and effective primary treatment even in large VSs. However, long-term tumor control rates are lower in comparison with small/medium-sized VSs. Thus, closer follow-up should be applied.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004735
- 003
- CZ-PrNML
- 005
- 20220127145030.0
- 007
- ta
- 008
- 220113s2021 sw f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)33714245
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Stastna, Daniela $u Department of Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
- 245 10
- $a Large vestibular schwannomas: long-term outcomes after stereotactic radiosurgery / $c D. Stastna, D. Urgosik, T. Chytka, R. Liscak
- 520 9_
- $a OBJECTIVES: Stereotactic radiosurgery (SRS) is an established treatment option of small/medium-sized vestibular schwannomas (VSs). Concerning management of the large VSs, primary SRS remains a controversial option. Our retrospective study analyzes long-term radiological and clinical outcomes of SRS in large VSs. MATERIAL AND METHODS: We retrospectively analyzed 73 patients with single large VS, treated with SRS. Inclusion criteria were: tumor volume >4 cm3, follow-up >2 years, radiological (3D-volumetric studies) and clinical follow-up. SRS was either primary (94.5%) or secondary (5.5%) treatment. The median marginal dose (50%-isodose line) was 12Gy (11.5-12Gy). Fisher exact test, t-test, ANOVA, Kaplan-Meier and Cox regression models were performed when appropriate RESULTS: The median follow-up was 5.5 years. The median VS volume at SRS was 6.5 cm3 (range 4-14.2 cm3). The tumor control rates assessed from Kaplan-Meier curve were 88.3%, 82.4% and 74.7% 5.8 and 10 years after SRS, respectively. Tumor shrinkage was observed in 83.6% of patients (n=61), unchanged volume in 4.1% patients (n=3) and progression in 12.3% (n=9). The median tumor volume significantly decreased to 4.0 cm3, measured at 5-year follow-up (p<0.0001). Large cystic VSs responded better to SRS then homogeneous. Pre-SRS serviceable hearing was present in 37% of patients; 55% of these had hearing preserved after treatment. After SRS, new facial palsy (House-Brackmann gr. III-VI) appeared in 4.1% of patients; 9.6% of patients had transient brainstem/cranial nerves edema. For tumor progression, 8.2% of patients underwent resection, 2.8% of patients repeated SRS. CONCLUSION: Our results are showing that SRS might be safe and effective primary treatment even in large VSs. However, long-term tumor control rates are lower in comparison with small/medium-sized VSs. Thus, closer follow-up should be applied.
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a vestibulární schwannom $x diagnostické zobrazování $x radioterapie $x chirurgie $7 D009464
- 650 12
- $a radiochirurgie $7 D016634
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a tumor burden $7 D047368
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Urgosik, Dusan $u Department of Stereotactic and Radiation Neurosurgery, Center for Epilepsy, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Chytka, Tomas $u Department of Stereotactic and Radiation Neurosurgery, Center for Epilepsy, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Liscak, Roman $u Department of Stereotactic and Radiation Neurosurgery, Center for Epilepsy, Na Homolce Hospital, Prague, Czech Republic
- 773 0_
- $w MED00168352 $t Neuro endocrinology letters $x 2354-4716 $g Roč. 41, č. 6 (2021), s. 329-338
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33714245 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145026 $b ABA008
- 999 __
- $a ok $b bmc $g 1752036 $s 1155884
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 41 $c 6 $d 329-338 $e - $i 2354-4716 $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
- LZP __
- $a Pubmed-20220113
